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RESEARCH ARTICLE

Open Access

Circulating tumor cells as early predictors of
metastatic spread in breast cancer patients with
limited metastatic dissemination
Mario Giuliano1,2,3†, Antonio Giordano3,4†, Summer Jackson5, Ugo De Giorgi3,6, Michal Mego3,7, Evan N Cohen3,
Hui Gao3, Simone Anfossi3, Beverly C Handy8, Naoto T Ueno5, Ricardo H Alvarez5, Sabino De Placido1,
Vicente Valero5, Gabriel N Hortobagyi5, James M Reuben3* and Massimo Cristofanilli5,9*

Abstract
Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict
treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based
markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease
monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in
breast cancer patients with limited metastatic dissemination.
Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to
starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood,
pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at
baseline and at the time of treatment failure, using Fisher’s exact test. Time to visceral progression and time to the
development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with
single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between
groups according to pretreatment CTC count by logrank test.
Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline
number of metastatic sites compared with <5 CTCs/7.5 ml (P = 0.0077). At the time of treatment failure, patients
with ≥5 CTCs/7.5 ml more frequently developed new metastatic lesions and sites compared with those with <5
CTCs/7.5 ml (development of new lesions: P = 0.0002; development of new sites: P = 0.0031). Among patients with
disease originally confined to nonvisceral sites, ≥5 CTCs/7.5 ml was associated with remarkably shorter time to
visceral metastases (P = 0.0021) and overall survival (P = 0.0006) compared with <5 CTCs/7.5 ml. In patients with
single-site metastatic disease, ≥5 CTCs/7.5 ml was associated with a significant reduction of the time to development
of new metastatic sites (P = 0.0051) and new lesions (P = 0.0002) and with worse overall survival (P = 0.0101).
Conclusion: Our results suggest that baseline CTC counts can be used as an early predictor of metastatic potential in
breast cancer patients with limited metastatic dissemination.
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Introduction
Breast cancer mortality has decreased considerably over
the past two decades as a result of earlier diagnosis and
major treatment advances in the adjuvant and metastatic
settings [1]. Despite this progress, metastatic disease is
still largely considered an incurable condition, and 5year survival rates are <25% [1]. However, metastatic
breast cancer is a heterogeneous disease, and long-term
patient outcomes can be influenced by various biological
features, as well as by the extent and site of metastatic
disease. On the one hand, widespread visceral disease is
typically associated with symptoms leading to deterioration of performance status and short survival [2]. On the
other hand, limited metastatic dissemination, primarily
confined to nonvisceral tissues, is more frequently associated with an indolent disease course and prolonged survival [3-5]. Nevertheless, the current standard assessment
of metastatic disease by morphological and functional imaging does not provide adequate information on tumor
biology and the presence of micrometastases, limiting the
possibility to predict tumor metastatic potential [3].
During the past decade, several techniques capable of
detecting and quantifying circulating tumor cells (CTCs)
in cancer patients have been developed [4,5]. It has been
proposed that subpopulations of CTCs with tumorinitiating potential act as a central mediator of metastatic dissemination, giving rise to the formation of
distant micrometastases, which subsequently generate
overt detectable and frequently measurable lesions [6].
In support of this theory, multiple studies have shown
that ≥5 CTCs/7.5 ml of blood, counted using the CellSearch System (Janssen Diagnostics, Raritan, NJ, USA)
and evaluated before starting systemic treatment, is associated with poor outcome in patients with metastatic breast
cancer [7-10]. In addition, high CTC counts are associated
with greater metastatic tumor burden, expressed as the
number of metastatic sites [8,11]. Importantly, despite this
association, the prognostic value of CTCs is independent
from the initial number of metastatic sites [8,11]. This
may suggest that the negative prognostic impact of high
CTC counts is not merely expression of the overt tumor
burden, but also may reflect higher biological aggressiveness and presence of undetectable micrometastatic disease, and ultimately may predict a greater tendency to
metastatic spread.
Therefore, we hypothesized that CTC counts, when
evaluated prior to starting systemic treatment, represent
an early marker of metastatic spread and are useful primarily in patients with limited metastatic dissemination
and potentially eligible for locoregional treatments with
a curative intent [12-14]. To test our hypothesis, we analyzed the patterns of recurring metastatic dissemination
in patients with advanced breast cancer who had a CTC
count before starting a new line of systemic treatment.
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Methods
Study design

In this study, we conducted a retrospective analysis of a
preexisting database including 517 metastatic breast
cancer patients treated at The University of Texas MD
Anderson Cancer Center between September 2002 and
November 2009. All the patients had a CTC count using
the CellSearch System before starting a new line of systemic treatment. From among the overall population,
492 women (95%) were selected for this analysis because
they had documented radiological follow-up. Eligible patients were categorized into two groups according to
baseline CTC counts using the well-established threshold of 5 CTCs/7.5 ml of blood [7,15] (<5 CTCs/7.5 ml
versus ≥5 CTCs/7.5 ml of blood). Radiologic disease assessments were performed in line with institutional
guidelines, and progression of disease (PD) was defined
according to the Response Evaluation Criteria In Solid
Tumors (RECIST) [16]. Reports based on radiologic assessments performed in each patient after baseline CTC
evaluation were reviewed. The type of PD was recorded
and classified as appearance of new metastatic lesions,
either within the preexisting sites or in new metastatic
sites, or as dimensional increase of the preexisting lesions. These analyses were performed in the overall
population and selectively in patients with limited metastatic dissemination at baseline, defined as disease confined to nonvisceral organs or to a single organ. The
Institutional Review Board at MD Anderson Cancer
Center approved the study (DR10-0227) and granted a
waiver of informed consent, considering the retrospective nature of this analysis. Clinical data from the MD
Anderson Cancer Center’s electronic medical records
were collected by two physicians (AG and MG).
Isolation and enumeration of circulating tumor cells

Peripheral blood samples (7.5 ml) collected within
30 days before starting any systemic treatment were
drawn into CellSave tubes and processed within 72 hours
of collection. The standardized US Food and Drug
Administration–cleared CellSearch System was used to
isolate and count CTCs as previously reported [17].
CTCs were defined as nucleated, epithelial cell adhesion
molecule (EpCAM)–positive cells, expressing cytoplasmic cytokeratins 8, 18 and 19, but lacking expression of
the common leukocyte antigen CD45. All CTC evaluations were performed by qualified personnel in a pathology laboratory certified in accordance with the Clinical
Laboratory Improvement Amendments.
Statistical analysis

The rate of new metastatic sites and new metastatic
lesions, the number of new metastatic sites developed at
the time of first PD (one or at least two) and the differences
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in the organ distribution of metastatic sites were compared between the two CTC groups using Fisher’s exact
test. The number of metastatic sites present at baseline
(one, two or three or more) and the type of systemic
treatment were compared between the CTC groups
using Pearson’s χ2 test. Time to PD was defined as the
interval between baseline CTC count and PD or death.
Overall survival was defined as the time elapsed between initial CTC assessment and patient death. In patients with disease confined to a single organ, time to
new metastatic sites was calculated from baseline to the
appearance of new metastatic sites. In the same group,
time to new metastatic lesions indicated the interval between baseline CTC count and development of new
metastatic lesions, either in preexisting sites or at new
sites. Time to visceral disease was defined as the interval
between baseline and development of visceral metastases
in patients with disease initially confined to nonvisceral
organs. For the estimation of all of the aforementioned
survival times, in the absence of the specific event,
patients were censored at the date of the last follow-up.
Each survival time was estimated using the Kaplan-Meier
product limit method and compared between the CTC
groups (<5 CTCs/7.5 ml versus ≥5 CTCs/7.5 ml) by logrank test. Multivariate survival analysis was performed
using Cox’s regression. All the statistical analyses,
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performed using the PASW Statistical Analysis for Social
Sciences (SPSS) statistics software (SPSS, Chicago, IL,
USA), were two-sided, and P-values <0.05 were considered
statistically significant.

Results
Pretreatment circulating tumor cell counts correlated
with extent and site of metastatic disease at baseline

Baseline patient and tumor characteristics stratified by
CTC counts are reported in Table 1. Among the patient
sample, 303 (61.6%) had <5 CTCs/7.5 ml and 189
(38.4%) had ≥5 CTCs/7.5 ml. No significant difference in
terms of treatment strategy (systemic treatment only
versus additional locoregional treatment) and line of systemic treatment was found between the CTC groups
(Table 1). Conversely, the type of systemic treatment significantly differed, with a higher percentage of patients
receiving chemotherapy and a lower percentage receiving endocrine and other therapies in the group with ≥5
CTCs/7.5 ml compared with <5 CTCs/7.5 ml (P =
0.0041) (Table 1). The distribution of the immunohistochemically defined tumor subtypes stratified by CTC
value was previously reported and did not show significant differences between the CTC groups [8]. Also, in
line with previously published reports [8,18], high baseline CTC counts were associated with greater metastatic

Table 1 Baseline patient and tumor characteristics stratified by circulating tumor cell count
Variable

Overall, N (%)

CTCs <5/7.5 ml, n (%)

CTCs ≥5/7.5 ml, n (%)

P-value

Overall population

492 (100)

303 (61.6)

189 (38.4)

–

Systemic treatment only

467 (94.9)

286 (94.7)

180 (95.2)

ns

Additional locoregional treatment

25 (5.1)a

16 (5.3)

9 (4.8)

First

232 (47.2)

139 (45.9)

93 (49.2)

Second or later

260 (52.8)

164 (54.1)

96 (50.8)

Treatment strategy

Line of treatment
ns

Type of systemic treatment
Chemotherapy

376 (76.4)

218 (71.9)

158 (83.6)

Endocrine therapy

103 (20.9)

73 (24.1)

30 (15.9)

0.0041

Other

13 (2.7)

12 (4.0)

1 (0.5)

1

146 (29.7)

104 (34.3)

42 (22.2)

2

145 (29.5)

89 (29.4)

56 (29.6)

≥3

201 (40.8)

110 (36.3)

91 (48.2)

Lymph nodes/soft tissuesb

58 (11.8)

48 (15.8)

10 (5.3)

0.0003

Bonec

326 (66.2)

172 (56.8)

154 (81.5)

<0.0001

Number of metastatic sites
0.0077

Distribution of metastatic sites

d

a

Viscera

306 (62.2)

184 (60.7)

122 (64.6)

ns

Braine

37 (7.5)

23 (7.6)

14 (7.4)

ns

Additional locoregional treatments: surgery 15 (3.0%); radiation therapy 8 (1.6%); other 2 (0.4%). bLymph nodes/soft tissue only. cBone with or without other sites.
Visceral organs (including brain) with or without other sites. eBrain with or without other sites. CTCs, Circulating tumor cells; ns, Statistically nonsignificant.

d
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tumor burden and higher frequency of bone involvement (Table 1). The percentage of cases with disease
confined to lymph nodes and/or soft tissues was significantly higher in the group with low CTCs compared
with that of patients with high CTCs (Table 1).
Pretreatment circulating tumor cell counts correlated
with magnitude of metastatic dissemination at the time
of disease progression

At the time of this analysis, the median follow-up among
living patients was 32.2 months in the overall population
(33.4 months in the group with <5 CTCs/7.5 ml and
30.6 months in the group with ≥ 5 CTCs/7.5 ml). Among
the two groups, 264 patients (87.1%) with <5 CTCs/
7.5 ml and 178 (94.2%) with ≥5 CTCs/7.5 ml had experienced PD before the last follow-up visit. Median times
to the first PD were 6.8 months (95% CI: 5.8 to
7.8 months) in subjects with <5 CTCs/7.5 ml and 5.9
(95% CI: 5.0 to 6.8 months) in those with ≥5 CTCs/
7.5 ml (P = 0.0059). The extent of metastatic spread occurring at the time of the first PD after CTC assessment
was evaluated and correlated with the baseline CTC
counts. The development of new metastatic sites was
significantly more frequent among patients with ≥5
CTCs/7.5 ml compared to those with <5 CTCs/7.5 ml
(P = 0.0031) (Figure 1A). Similarly, the development of
new metastatic lesions, either within the preexisting sites
or in new metastatic sites, was more frequent in the
group of patients with ≥5 CTCs/7.5 ml (P = 0.0002)
(Figure 1B). In addition, the number of new metastatic
sites that developed at the time of first PD was significantly higher in the patients with ≥5 CTCs/7.5 ml compared to those with <5 CTCs/7.5 ml (P = 0.0083)
(Figure 1C). All of these findings translated into a marked
difference in long-term outcomes, with median overall
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survival of 31.5 months (95% CI: 23.9 to 39.1 months) for
patients with <5 CTCs/7.5 ml versus 19.1 (95% CI: 15.9 to
22.3 months) for those with ≥5 CTCs/7.5 ml (P = 0.0001).
Pretreatment circulating tumor cell counts correlated
with visceral disease spread at the time of disease
progression

At the time of the first PD, similar to baseline, the frequency of cases with metastatic disease confined to
lymph nodes and/or soft tissues was higher among patients with <5 CTCs/7.5 ml than in patients with ≥5
CTCs/7.5 ml (P = 0.0009) (Table 2). In addition, after
PD, the rate of visceral metastases became significantly
higher in the group of patients with ≥5 CTCs/7.5 ml
(P = 0.0114) (Table 2). Of note, we also observed a trend
for a higher frequency of brain metastases in patients
with ≥5 CTCs/7.5 ml (P = 0.0865) (Table 2).
To further assess the correlation between CTC counts
and visceral disease spread, we analyzed the patterns of
metastatic dissemination selectively in 186 patients
(37.8%) with disease initially confined to nonvisceral organs. Of those, 119 (64%) had <5 CTCs/7.5 ml and 67
(36%) had ≥5 CTCs/7.5 ml. A total of 149 patients with
nonvisceral metastases experienced PD by the time of
their last visit. Among these patients, the development
of visceral metastases was significantly more frequent in
the group with ≥5 CTCs/7.5 ml compared to the group
with <5 CTCs/7.5 ml (40.7% versus 17.8%, respectively;
(P = 0.012) (Figure 2A). Also, the time to the development of visceral disease was remarkably different between the CTC groups (42.1 months versus 15.9 months
in women with <5 CTCs/7.5 ml versus ≥5 CTCs/7.5 ml,
respectively; P = 0.0021) (Figure 2B). The multivariate
analysis demonstrated that the effect of CTC counts on
time to visceral disease was independent from other

Figure 1 Association of baseline circulating tumor cell counts with metastatic spread in the overall population. (A) and (B) Rates of
development of new metastatic sites (A) and new lesions (B) refer to the first progression of disease (PD) after baseline in the overall population
(N = 492), stratified by circulating tumor cell (CTC) count. (C) Number of new metastatic sites that had developed by the first PD after baseline in
patients whose disease had progressed in new sites (n = 121), stratified by CTC count.
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Table 2 Distribution of metastatic sites after treatment failure stratified by pretreatment circulating tumor cell counta
Overall, N (%)

CTCs <5/7.5 ml, n (%)

CTCs ≥5/7.5 ml, n (%)

P-value

48 (9.8)

40 (13.2)

8 (4.2)

0.0009

Bone

337 (68.5)

180 (59.4)

157 (83.1)

<0.0001

Viscerad

344 (69.9)

199 (65.7)

145 (76.7)

0.0114

59 (12.0)

30 (9.9)

29 (15.3)

0.0865

Lymph nodes/soft tissuesb
c

e

Brain
a

Treatment failure was defined as first disease progression after the baseline CTC evaluation. bLymph nodes/chest soft tissue only. cBone with or without other
sites. dVisceral organ (including brain) with or without other sites. eBrain with or without other sites.

prognostic variables, including estrogen receptor (ER)
and human epidermal growth factor receptor 2 (HER2)
status, baseline number of metastatic sites and presence
of bone metastases (Additional file 1: Table S1). By the
time of the last follow-up visit, 53 (44.5%) of the 119 patients with <5 CTCs/7.5 ml and only 14 (20.9%) of the
67 with ≥5 CTCs/7.5 ml were free of visceral disease
(P = 0.0229). As expected, all of these findings were accompanied by a highly significant difference in overall
survival between the CTC groups (57.9 months for patients with CTCs <5 CTCs/7.5 ml versus 27.3 months
for those with ≥5 CTCs/7.5 ml; P = 0.0006).
Pretreatment circulating tumor cell counts correlated
with metastatic dissemination in patients with disease
originally confined to a single organ

The impact of high CTC counts on metastatic dissemination was also evaluated selectively in 146 patients
(29.7%) with disease originally confined to a single
organ. In this group, 104 women (71.2%) had <5 CTCs/
7.5 ml and 42 (28.8%) had ≥5 CTCs/7.5 ml at the baseline evaluation (Table 3). No statistically significant difference was found between the two CTC groups in
terms of treatment strategy (systemic treatment alone or
systemic treatment plus additional locoregional treatment) and type of systemic treatment (chemotherapy,
endocrine therapy or other). On the contrary, the

anatomical distribution of the metastatic sites was significantly different between the CTC groups, with bone
metastases more frequent in patients with ≥5 CTCs/
7.5 ml and soft-tissue/lymph node involvement more
frequent among those with <5 CTCs/7.5 ml (P = 0.023)
(Table 3). Median time to first PD was 12.2 months for
patients with <5 CTCs/7.5 ml and 7.1 months for those
with ≥5 CTCs/7.5 ml (P = 0.0373). Among the patients
who experienced PD, those with ≥5 CTCs/7.5 ml more
frequently developed new metastatic lesions, either
within the preexisting sites or in new metastatic sites,
compared to patients with <5 CTCs/7.5 ml (88.9%
versus 56.6%, respectively; P = 0.0031) (Figure 3A).
Moreover, the time to the development of new metastatic sites was remarkably longer in patients with low
CTC counts compared to those with high counts
(40.2 months versus 15.9 months for patients with <5
CTCs/7.5 ml versus ≥5 CTCs/7.5 ml, respectively; P =
0.0051) (Figure 3B). Similarly, there was a striking difference in the length of time to development of new
metastatic lesions between the two CTC groups
(17.7 months for patients with <5 CTCs/7.5 ml versus
7.2 months for those with ≥5 CTCs/7.5 ml; P = 0.0002)
(Figure 3C). Importantly, the multivariate analysis
showed that these differences were not dependent on
other variables, including ER and HER2 status and
presence of visceral or bone metastases at baseline

Figure 2 Association of baseline circulating tumor cell counts with visceral disease spread. (A) Types of the first progression of
disease (PD) occurring after baseline in 149 patients with disease initially confined to nonvisceral organs, stratified by circulating tumor cell
(CTC) count. Thirty-seven (19.9%) of the total of one hundred eighty-six patients without baseline visceral metastases had not developed PD
before the last follow-up visit. (B) and (C) Time to visceral disease (B) and overall survival (C) in the 186 patients without visceral metastases,
stratified by CTC count.
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Table 3 Baseline tumor features and treatments in patients with disease confined to a single organa
Variable

Overall, N (%)

CTCs <5/7.5 ml, n (%)

CTCs ≥5/7.5 ml, n (%)

P-value

Overall population

146 (100)

104 (71.2)

42 (28.8)

–

Positive

99 (67.8)

67 (64.4)

32 (76.2)

ns

Negative

47 (32.2)

37(35.6)

10 (23.8)

HER2 amplified/overexpressed

30 (20.6)

22 (21.2)

8 (19.1)

HER2 normal

116 (79.4)

82 (78.8)

34 (80.9)

129 (88.4)

91 (87.5)

38 (90.5)

b

13 (12.5)

4 (9.5)

HR status

HER2 status
ns

Treatment strategy
Systemic treatment only
Additional locoregional treatment

17 (11.6)

ns

Type of systemic treatment
Chemotherapy

101 (69.2)

70 (67.3)

31 (73.8)

Endocrine therapy

41 (28.1)

31 (29.8)

10 (23.8)

Other

4 (2.7)

3 (2.9)

1 (2.4)

ns

Distribution of metastatic sites
Lymph nodes/soft tissues

50 (34.2)

41 (39.4)

9 (21.4)

Bone

68 (46.6)

41 (39.4)

27 (64.3)

Viscera

28 (19.2)

22 (21.2)

6 (14.3)

0.023

a

CTCs, Circulating tumor cells; HER2, Human epidermal growth factor receptor 2; HR, Hormone receptor; ns, Statistically nonsignificant. bAdditional locoregional
treatments: surgery in 12 patients (8.2%), radiation therapy in 4 patients (2.7%) and other for 1 patient (0.7%).

(Additional file 1: Table S1). Unsurprisingly, all of these
findings translated to a significant difference in long-term
outcomes (overall survival: 40.3 months versus >60 months
for patients with ≥5 CTCs/7.5 ml versus <5 CTCs/7.5 ml,
respectively; P = 0.0101) (Figure 3D).

Discussion
Systemic metastatic spread represents the main cause of
breast cancer–related morbidity and death. Thus, for patients in the advanced stages of disease, it is critical to
improve treatment strategies that may affect not only
proliferation but also migration and invasion, important
features of the metastatic process. The traditional factors
currently used for prognostic stratification and treatment
decisions in the advanced stages of breast cancer, including hormone receptor and HER2 status, site and extent
of metastatic burden, and length of disease-free interval,
often do not adequately predict treatment response and
disease evolution. In addition, treatment aggressiveness
is still debated in the presence of disease confined to
nonvisceral organs or asymptomatic visceral metastases.
In this scenario, the use of blood-based disease monitoring, such as CTC assessment, may represent a complementary and informative strategy [19-23]. Recently, the
results of a prospective clinical trial confirmed the
strong prognostic value of CTCs in metastatic breast
cancer patients [10,24]. Moreover, a large pooled analysis
of individual patient data showed that adding CTC

count status to clinicopathological predictive models significantly improved survival prognostication in advanced
breast cancer [24]. The results of our present study suggest a novel role for CTCs as predictors of disease evolution in patients with advanced breast cancer, particularly
those with limited metastatic dissemination. We found
that pretreatment CTC counts ≥5/7.5 ml correlated with
greater metastatic dissemination at the time of treatment
failure, owing to more frequent appearance of new metastatic lesions and sites. Also, the extent of the newly developed metastatic burden was greater in patients with ≥5
CTCs/7.5 ml compared with those with <5 CTCs/7.5 ml
[6]. We can hypothesize that elevated CTC numbers,
when observed prior to starting systemic treatment, may
reveal greater propensity to metastatic seeding and more
extensive micrometastatic disease and thus may function
as an early predictor of overt metastatic spread. This
further emphasizes the need to investigate the molecular
features of these cells in addition to their prognostic value.
Expectedly, CTC counts ≥5/7.5 ml were also associated
with lower frequency of disease confined to nonhematogenous metastatic sites, such as lymph nodes and soft
tissues. Importantly, among the patients with nonvisceral
metastases in our sample, ≥5 CTCs/7.5 ml predicted
higher risk of visceral progression. This finding could have
important clinical implications. Indeed, it is generally recommended that aggressive treatment strategies, such as
chemotherapy-based regimens, are needed in cases of
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Figure 3 Association of baseline circulating tumor cell counts with metastatic spread in patients with single-site disease. (A) Type of
the first progression of disease (PD) occurring after baseline in 112 patients with single metastatic site disease, stratified by circulating tumor
cell (CTC) count. Thirty-four (23.3%) of the total one hundred forty-six patients with single-site disease had not developed PD before the last
follow-up visit. (B), (C) and (D) Time to new metastatic sites (B), time to new metastatic lesions (C) and overall survival (D) in the 146 patients
with single metastatic site disease, stratified by CTC count.

widespread visceral metastases and rapidly progressive disease [25,26]. On the basis of our results, it can be proposed that pretreatment CTC counts may identify in
advance patients who have higher risk of developing widespread visceral disease and consequently might benefit
from early administration of more aggressive systemic
treatments. Nevertheless, the retrospective nature of our
analysis suggests the need to prospectively validate the use
of CTCs as surrogate markers of metastatic potential, together with the investigation of new therapeutic strategies
aimed at targeting biological properties of CTCs, with the
goal of preventing or delaying PD and possibly improving
patient outcomes [27,28].
The link between micrometastatic disease and CTCs,
as well as their capability to predict overt metastatic
dissemination, may have important implications in
the clinical management of patients with single-site

metastatic disease. Indeed, among patients with this
specific condition, pretreatment CTC counts ≥5/7.5 ml
were correlated with higher risk of developing new
metastatic sites and lesions at the time of treatment
failure. This may imply limited value of combined
therapeutic modalities that include local therapies in
patients with high CTC counts. However, 43% of
patients with single-site disease and <5 CTCs/7.5 ml
experienced dimensional increases in the preexisting
lesions when treatment resistance occurred. Hence,
pretreatment CTC counts <5/7.5 ml may identify a
subgroup of patients with single-organ disease who
have higher probability of maintaining this condition
for a longer time upon systemic treatment and for
whom locoregional ablative procedures, if feasible,
can contribute to symptom control and prolong survival [12-14].

Giuliano et al. Breast Cancer Research 2014, 16:440
http://breast-cancer-research.com/content/16/5/440

The retrospective nature of the analyses and the lack
of CTC molecular profiling represent the main limitations of this study, principally because molecular heterogeneity of CTCs may influence their role in metastatic
seeding. In particular, specific subpopulations of CTCs
undergoing molecular reprogramming known as the
epithelial-to-mesenchymal transition (EMT) [29,30]
process lose their epithelial differentiation and acquire
a mesenchymal phenotype, with increased invasion
capabilities and stemness properties [30,31]. The results of several studies suggest that CTCs with EMT
features are the major effectors of metastatic seeding
and are responsible for tumor progression [32-35].
Importantly, in the presence of the EMT process and
loss of epithelial markers, EpCAM-based isolation
methods, such as the CellSearch System, do not perform adequately. Thus, sensitive new strategies for
CTC isolation and analysis are needed in order to thoroughly use these cells for prediction of disease evolution [36,37].
Despite these limitations, our study is clinically relevant because we propose, for the first time to our knowledge, a potential marker of disease spread in breast
cancer patients with limited metastatic dissemination.

Conclusion
Our findings suggest a new potential role for pretreatment CTC counts as early predictors of metastatic potential. This type of evaluation may be useful for
improved risk stratification in patients with nonvisceral
disease and single-organ metastatic involvement. Considering the limited number of patients evaluated in our
study, our results warrant larger studies based on CTC
enumeration and molecular profiling to develop novel
treatment decision tools for breast cancer patients with
limited metastatic dissemination.
Additional file
Additional file 1: Table S1. Multivariate analysis.
Abbreviations
CTC: Circulating tumor cell; EMT: Epithelial-to-mesenchymal transition;
EpCAM: Epithelial cell adhesion molecule; ER: Estrogen receptor;
HER2: Human epidermal growth factor receptor 2; RECIST: Response
Evaluation Criteria In Solid Tumors; SPSS: Statistical Package for Social
Science.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MG and AG conceived of and designed the study, collected clinical data,
performed data analysis and interpretation, and drafted the manuscript. SJ
performed the CellSearch CTC analysis of all patients and contributed to data
interpretation and manuscript drafting and revision. UDG and MM collected
clinical data and contributed to data interpretation and manuscript drafting
and revision. EC and HG performed data analysis and contributed to data

Page 8 of 9

interpretation and manuscript drafting and revision. SA performed data
analysis and contributed to manuscript drafting and revision. BCH performed
pathological review of CTC images in the Clinical Laboratory Improvement
Amendments–certified pathology laboratory and contributed to data
interpretation and manuscript revision. NTU, RHA, VV and GNH provided
clinical assessment of patients and contributed to analysis, study conception
and manuscript revision. SDP performed data analysis and contributed to
analysis, study conception and manuscript revision. JMR and MC conceived
of and designed the study, performed data analysis and interpretation, and
contributed to manuscript drafting and revision. All authors substantially
participated in manuscript revision. All authors agree to be accountable for
all aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved.
All authors read and approved the final manuscript.
Authors’ information
The authors’ affiliations at the time of study design, data collection and
analysis were as follows. MG, UDG, MM and ENC: Department of
Hematopathology, The University of Texas MD Anderson Cancer Center,
Houston, TX, USA. MC: Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA.
Author details
1
Department of Clinical Medicine and Surgery, University Federico II, Naples,
Italy. 2Lester and Sue Smith Breast Center, Baylor College of Medicine,
Houston, TX, USA. 3Department of Hematopathology, The University of Texas
MD Anderson Cancer Center, Houston, TX, USA. 4Department of Internal
Medicine, Medical University of South Carolina, Charleston, SC, USA. 5Breast
Medical Oncology, The University of Texas MD Anderson Cancer Center,
Houston, TX, USA. 6Medical Oncology, Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori, Meldola, FC, Italy. 7Department of Medical
Oncology, School of Medicine, Comenius University, Bratislava, Slovakia.
8
Laboratory Medicine, The University of Texas MD Anderson Cancer Center,
Houston, TX, USA. 9Breast Program, Sidney Kimmel Cancer Center, Thomas
Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107,
USA.
Received: 14 May 2014 Accepted: 1 September 2014

References
1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF,
Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS,
Feuer EJ, Cronin KA (Eds): SEER Cancer Statistics Review, 1975–2010. Bethesda,
MD: National Cancer Institute; http://seer.cancer.gov/csr/1975_2010/, based
on November 2012 SEER data submission, posted to the SEER web site,
April 2013.
2. Yardley DA: Visceral disease in patients with metastatic breast cancer:
efficacy and safety of treatment with ixabepilone and other
chemotherapeutic agents. Clin Breast Cancer 2010, 10:64–73.
3. Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B: Monitoring in
metastatic breast cancer: is imaging outdated in the era of circulating
tumor cells? Breast Care 2014, 9:16–21.
4. Alix-Panabières C, Pantel K: Technologies for detection of circulating
tumor cells: facts and vision. Lab Chip 2014, 14:57–62.
5. Esmaeilsabzali H, Beischlag TV, Cox ME, Parameswaran AM, Park EJ:
Detection and isolation of circulating tumor cells: principles and
methods. Biotechnol Adv 2013, 31:1063–1084.
6. Pantel K, Alix-Panabières C, Riethdorf S: Cancer micrometastases. Nat Rev
Clin Oncol 2009, 6:339–351.
7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM,
Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells,
disease progression, and survival in metastatic breast cancer. N Engl J
Med 2004, 351:781–791.
8. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC,
Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi
GN, Reuben JM, Cristofanilli M: Circulating tumor cells in
immunohistochemical subtypes of metastatic breast cancer: lack of
prediction in HER2-positive disease treated with targeted therapy.
Ann Oncol 2012, 23:1144–1150.

Giuliano et al. Breast Cancer Research 2014, 16:440
http://breast-cancer-research.com/content/16/5/440

9.

10.

11.

12.
13.
14.

15.

16.

17.

18.

19.

20.

21.

22.

23.
24.

25.

26.

Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM,
Pierga JY, Cristofanilli M, Bidard FC: Establishment and validation of
circulating tumor cell-based prognostic nomograms in first-line metastatic
breast cancer patients. Clin Cancer Res 2013, 19:1596–1602.
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G,
Tejwani S, Schott AF, O’Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston
RB, Hayes DF: Circulating tumor cells and response to chemotherapy in
metastatic breast cancer: SWOG S0500. J Clin Oncol. in press. doi:10.1200/
JCO.2014.56.2561.
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy
BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V,
Hortobagyi GN, Reuben JM, Cristofanilli M: Circulating tumor cells as
prognostic and predictive markers in metastatic breast cancer patients
receiving first-line systemic treatment. Breast Cancer Res 2011, 13:R67.
Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13:8–10.
Weichselbaum RR, Hellman S: Oligometastases revisited. Nat Rev Clin Oncol
2011, 8:378–382.
Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A,
Winer EP, Cardoso F, the ESMO-MBC Task Force: International guidelines
for management of metastatic breast cancer: can metastatic breast
cancer be cured? J Natl Cancer Inst 2010, 102:456–463.
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R,
Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM:
Artificial neural network analysis of circulating tumor cells in metastatic
breast cancer patients. Breast Cancer Res Treat 2011, 129:451–458.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L,
Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009,
45:228–247.
Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV,
Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW:
Circulating tumor cells: a novel prognostic factor for newly diagnosed
metastatic breast cancer. J Clin Oncol 2005, 23:1420–1430. A published
erratum appears in J Clin Oncol 2005, 23:4808.
De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT,
Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M:
Circulating tumor cells and bone metastases as detected by FDG-PET/CT
in patients with metastatic breast cancer. Ann Oncol 2010, 21:33–39.
Dong X, Alpaugh KR, Cristofanilli M: Circulating tumor cells (CTCs) in
breast cancer: a diagnostic tool for prognosis and molecular analysis.
Chin J Cancer Res 2012, 24:388–398.
Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth
A, Hayes DF, Kapke G, Kumar P, Lee J, Liu MC, McCormack R, Mikulski S,
Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT,
Schade AE, Scher HI, Sigman CC, Kelloff GJ: Considerations in the
development of circulating tumor cell technology for clinical use.
J Transl Med 2012, 10:138.
Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J,
Repollet M, Doyle GV, Terstappen LWMM, Hayes DF: Circulating tumor cells
versus imaging—predicting overall survival in metastatic breast cancer.
Clin Cancer Res 2006, 12:6403–6409.
Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB,
Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C: Circulating tumor
cells: a useful predictor of treatment efficacy in metastatic breast cancer.
J Clin Oncol 2009, 27:5153–5159.
Hayes DF, Smerage J: Is there a role for circulating tumor cells in the
management of breast cancer? Clin Cancer Res 2008, 14:3646–3650.
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D,
Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P,
Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M,
Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J,
Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C,
Rutten A, et al: Clinical validity of circulating tumour cells in patients with
metastatic breast cancer: a pooled analysis of individual patient data.
Lancet Oncol 2014, 15:406–414.
Wilcken N, Hornbuckle J, Ghersi D: Chemotherapy alone versus endocrine
therapy alone for metastatic breast cancer. Cochrane Database Syst Rev
2003, (2):CD002747.
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P,
Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M,

Page 9 of 9

27.

28.

29.

30.

31.
32.

33.

34.

35.

36.

37.

Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N,
Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo
H, Sacchini V, Sledge G, et al: 1st international consensus guidelines for
advanced breast cancer (ABC 1). Breast 2012, 21:242–252.
Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R,
Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D,
Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C,
Toner M, Maheswaran S, Haber DA: Cancer therapy: ex vivo culture of
circulating breast tumor cells for individualized testing of drug
susceptibility. Science 2014, 345:216–220.
Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J,
Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS:
CXCR1 blockade selectively targets human breast cancer stem cells
in vitro and in xenografts. J Clin Invest 2010, 120:485–497.
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell
and epithelial-mesenchymal transition markers are frequently overexpressed
in circulating tumor cells of metastatic breast cancer patients. Breast Cancer
Res 2009, 11:R46.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J,
Weinberg RA: The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell 2008, 133:704–715.
Guarino M, Rubino B, Ballabio G: The role of epithelial-mesenchymal
transition in cancer pathology. Pathology 2007, 39:305–318.
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano
JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel
E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S:
Circulating breast tumor cells exhibit dynamic changes in epithelial and
mesenchymal composition. Science 2013, 339:580–584.
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M,
Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ,
Cristofanilli M, Reuben JM: Epithelial–mesenchymal transition and stem cell
markers in patients with HER2-positive metastatic breast cancer. Mol Cancer
Ther 2012, 11:2526–2534.
Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y,
Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM:
Prognostic value of EMT-circulating tumor cells in metastatic breast
cancer patients undergoing high-dose chemotherapy with autologous
hematopoietic stem cell transplantation. J Cancer 2012, 3:369–380.
Liu H, Zhang X, Li J, Sun B, Qian H, Yin Z: The biological and clinical
importance of epithelial-mesenchymal transition in circulating tumor
cells. J Cancer Res Clin Oncol. in press. doi:10.1007/s00432-014-1752-x.
Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE:
Circulating tumour cells: the evolving concept and the inadequacy of
their enrichment by EpCAM-based methodology for basic and clinical
cancer research. Ann Oncol 2014, 25:1506–1516.
Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens
JW, Gratama JW, Sleijfer S, Foekens JA: Anti-epithelial cell adhesion
molecule antibodies and the detection of circulating normal-like breast
tumor cells. J Natl Cancer Inst 2009, 101:61–66.

doi:10.1186/s13058-014-0440-8
Cite this article as: Giuliano et al.: Circulating tumor cells as early
predictors of metastatic spread in breast cancer patients with limited
metastatic dissemination. Breast Cancer Research 2014 16:440.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

